表紙
市場調査レポート

PharmaEssentia Corporation:製品パイプライン分析

PharmaEssentia Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 219742
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaEssentia Corporation:製品パイプライン分析 PharmaEssentia Corporation - Product Pipeline Review - 2015
出版日: 2015年07月15日 ページ情報: 英文 33 Pages
概要

PharmaEssentia Corporation は本態性血小板血症、癌、慢性骨髄性白血病、肝炎、骨髄線維症、真性赤血球増加症などのような骨髄増殖性腫瘍を治療するための薬剤候補を開発しているバイオ製薬会社です。

当レポートでは、PharmaEssentia Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

PharmaEssentia Corporationの基本情報

PharmaEssentia Corporationの概要

  • 主要情報
  • 企業情報

PharmaEssentia Corporation:R&Dの概要

  • 主な治療範囲

PharmaEssentia Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

PharmaEssentia Corporation:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

PharmaEssentia Corporation:薬剤プロファイル

  • (paclitaxel + HM30181A)
  • peginterferon alfa-2b
  • P-1116
  • PEG-FSH
  • pegfilgrastim

PharmaEssentia Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

PharmaEssentia Corporation:最近のパイプライン動向

PharmaEssentia Corporation:休止中のプロジェクト

PharmaEssentia Corporation:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07323CDB

Summary

Global Markets Direct's, 'PharmaEssentia Corporation - Product Pipeline Review - 2015', provides an overview of the PharmaEssentia Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PharmaEssentia Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of PharmaEssentia Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of PharmaEssentia Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the PharmaEssentia Corporation's pipeline products

Reasons to buy

  • Evaluate PharmaEssentia Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of PharmaEssentia Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the PharmaEssentia Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of PharmaEssentia Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmaEssentia Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of PharmaEssentia Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • PharmaEssentia Corporation Snapshot
    • PharmaEssentia Corporation Overview
    • Key Information
    • Key Facts
  • PharmaEssentia Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • PharmaEssentia Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • PharmaEssentia Corporation - Pipeline Products Glance
    • PharmaEssentia Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • PharmaEssentia Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • PharmaEssentia Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • PharmaEssentia Corporation - Drug Profiles
    • (paclitaxel + HM30181A)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ropeginterferon ALFA-2B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-1116
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-FSH
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Beta Thalassemia and Sickle Cell Anemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • PharmaEssentia Corporation - Pipeline Analysis
    • PharmaEssentia Corporation - Pipeline Products by Target
    • PharmaEssentia Corporation - Pipeline Products by Route of Administration
    • PharmaEssentia Corporation - Pipeline Products by Molecule Type
    • PharmaEssentia Corporation - Pipeline Products by Mechanism of Action
  • PharmaEssentia Corporation - Recent Pipeline Updates
  • PharmaEssentia Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • PharmaEssentia Corporation, Key Information
  • PharmaEssentia Corporation, Key Facts
  • PharmaEssentia Corporation - Pipeline by Indication, 2015
  • PharmaEssentia Corporation - Pipeline by Stage of Development, 2015
  • PharmaEssentia Corporation - Monotherapy Products in Pipeline, 2015
  • PharmaEssentia Corporation - Combination Treatment Modalities in Pipeline, 2015
  • PharmaEssentia Corporation - Partnered Products in Pipeline, 2015
  • PharmaEssentia Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • PharmaEssentia Corporation - Phase III, 2015
  • PharmaEssentia Corporation - Phase II, 2015
  • PharmaEssentia Corporation - Phase I, 2015
  • PharmaEssentia Corporation - Preclinical, 2015
  • PharmaEssentia Corporation - Pipeline by Target, 2015
  • PharmaEssentia Corporation - Pipeline by Route of Administration, 2015
  • PharmaEssentia Corporation - Pipeline by Molecule Type, 2015
  • PharmaEssentia Corporation - Pipeline Products by Mechanism of Action, 2015
  • PharmaEssentia Corporation - Recent Pipeline Updates, 2015
  • PharmaEssentia Corporation, Other Locations

List of Figures

  • PharmaEssentia Corporation - Pipeline by Top 10 Indication, 2015
  • PharmaEssentia Corporation - Pipeline by Stage of Development, 2015
  • PharmaEssentia Corporation - Monotherapy Products in Pipeline, 2015
  • PharmaEssentia Corporation - Partnered Products in Pipeline, 2015
  • PharmaEssentia Corporation - Pipeline by Top 10 Target, 2015
  • PharmaEssentia Corporation - Pipeline by Top 10 Route of Administration, 2015
  • PharmaEssentia Corporation - Pipeline by Top 10 Molecule Type, 2015
  • PharmaEssentia Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top